Q-omics provides the consensus-scored RAB6A profile across patient tissues and cancer cell-line models. RAB6A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RAB6A is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, RAB6A RNA expression shows 20,216 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where RAB6A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB6A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB6A survival associations across molecular data types. RAB6A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB6A RNA expression–survival associations across cancer types. High RAB6A expression shows unfavorable associations in ACC, PAAD, LIHC, BLCA and UVM, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RAB6A RNA expression.
This table summarizes RAB6A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RAB6A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB6A shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, BLCA, BRCA and CHOL. The THCA box plot shows higher RAB6A RNA expression in normal versus tumor tissue (log2 FC = −0.700, t-test p < 0.001).
This table shows molecular features associated with RAB6A in patient tissues and cancer cell lines. In patient samples, RAB6A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB6A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
